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Neural regulation of cancer: from mechanobiology
to inflammation
Tae-Hyung Kim1,2, Amy C Rowat2,3,6 and Erica K Sloan1,3,4,5,6
Despite recent progress in cancer research, the exact nature of malignant transformation and its progression is still not fully
understood. Particularly metastasis, which accounts for most cancer death, is a very complex process, and new treatment
strategies require a more comprehensive understanding of underlying regulatory mechanisms. Recently, the sympathetic nervous
system (SNS) has been implicated in cancer progression and beta-blockers have been identified as a novel strategy to limit
metastasis. This review discusses evidence that SNS signaling regulates metastasis by modulating the physical characteristics of
tumor cells, tumor-associated immune cells and the extracellular matrix (ECM). Altered mechanotype is an emerging hallmark of
cancer cells that is linked to invasive phenotype and treatment resistance. Mechanotype also influences crosstalk between tumor
cells and their environment, and may thus have a critical role in cancer progression. First, we discuss how neural signaling
regulates metastasis and how SNS signaling regulates both biochemical and mechanical properties of tumor cells, immune cells
and the ECM. We then review our current knowledge of the mechanobiology of cancer with a focus on metastasis. Next, we
discuss links between SNS activity and tumor-associated inflammation, the mechanical properties of immune cells, and how the
physical properties of the ECM regulate cancer and metastasis. Finally, we discuss the potential for clinical translation of our
knowledge of cancer mechanobiology to improve diagnosis and treatment.
Clinical & Translational Immunology (2016) 5, e78; doi:10.1038/cti.2016.18; published online 13 May 2016
More than four decades ago in 1971, U.S. President Richard Nixon
signed the National Cancer Act, resolving to find cures to combat this
devastating disease. Thanks to improved funding for cancer research
and tremendous research efforts, we now have a much deeper
knowledge of cancer etiology, pathogenesis, treatment and prevention.
Indeed, an increasing body of research enables us to better understand
the hallmark features of cancer and to devise therapeutics that target
those characteristics of the disease.1 As a result, the number of cancer
survivors in the U.S. has increased from 3 million in 1971 to
14.5 million in 2014.2 Despite this significant progress, we are still
far from curing most forms of cancer. This is in part because we still
do not have a fully integrated knowledge of cancer. Although our
understanding of how individual characteristics, such as angiogenesis
and inflammation, contribute to cancer progression has improved,
additional factors that affect cancer progression have emerged, such as
the physical properties of tumor cells and their microenvironment
(Figure 1). In addition, it is becoming apparent that cancer outcomes
are influenced by factors on multiple levels that range from subcellular
(genetics and gene transcription) to psychosocial (behavior, diet,
lifestyle factors and environmental exposure). In this review, we
explore the influence of chronic stress as a physiological factor that
influences cancer progression. We consider the impact of stress
signaling through the sympathetic nervous system (SNS) on tumor
cells and tumor-associated inflammation, and consider the possibility
that stress regulates the physical properties of cells to influence
metastasis and cancer progression.
THE SNS AND CANCER
Metastasis is a complex, multistep process in which tumor cells
spread through the body via a process of detachment, intravasation,
transit through systemic circulation, extravasation and colonization
(Figure 2).3 Throughout these steps, the tumor microenvironment can
impact tumor cell dissemination.4 Studies of physiological regulators
of metastasis identify the SNS as a component of the tumor
microenvironment that regulates multiple steps in metastasis.5,6
The SNS mediates a stress response by releasing neurotransmitters,
the catecholamines norepinephrine and epinephrine. These neuro-
transmitters are structurally similar and exert their effects by binding
to adrenoceptors. Epinephrine is mainly secreted from the adrenal
medulla, whereas norepinephrine is secreted from both the adrenal
medulla and sympathetic nerve terminals.7 SNS nerve fibers can
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directly innervate tumor tissue and metastatic targets. When chronic
stress activates the SNS, norepinephrine is released, which can bind
directly to β-adrenoceptors on cancer cells.8 Various other types of
cells are present in the tumor microenvironment, including immune
cells, fibroblasts and endothelial cells.9 Each of those cell types also
express β-adrenoceptors, allowing them to also respond to
neurotransmitters.10 In addition to being released locally from nerve
fibers in the proximity of cancer cells, epinephrine may be released
systemically from the adrenal gland during times of
stress11 and delivered through the vascular system to the tumor
microenvironment.12
Accumulating evidence from preclinical studies demonstrates the
important role of SNS signaling in regulating multiple hallmarks of
cancer. The SNS may impact tumor progression by modulating
systemic release of growth factors and mobilization of inflammatory
cells. SNS nerve fibers in the liver and white adipose tissue release
norepinephrine to trigger secretion of glucose, adipokines and pro-
inflammatory cytokines into the bloodstream.13,14 These factors may
provide a growth stimulus to cancer cells and induce tumor-associated
inflammation. In addition, SNS-mediated release of norepinephrine in
the lymph nodes, spleen and bone marrow regulates differentiation
and egress of immune cells. For example, SNS activation in the bone
marrow stimulates myeloid lineage immune cells such as monocytes
and neutrophils,15,16 which can migrate into the tumor and promote
metastasis.6 Activation of β-adrenoceptors promotes tumor cell
dissemination by increasing the density of intratumoral blood and
lymph vessels.17,18 Inflammation can also promote SNS-dependent
angiogenesis.6 SNS signaling also directly affects cancer cell behavior
by increasing invadopodia formation, which facilitates invasion and
escape from the tumor.19
MECHANOBIOLOGY AND CANCER
Although much is understood about how neural signaling regulates
many aspects of tumor biology, less is known about how the SNS
regulates the physical and mechanical properties of tumor cells
and other cell types in the tumor microenvironment. The mechanical
properties of cells determine how they sense and respond to external
mechanical cues and play crucial roles in myriad biological
functions.20 Mechanical phenotype or ‘mechanotype’ is the inherent
property of a cell that determines its capacity to deform: stiffer cells
deform less in response to mechanical load compared to softer cells.
Cells have both elastic and viscous characteristics, which are largely
determined by three main classes of cytoskeletal proteins: filamentous
actin (F-actin), intermediate filaments and microtubules. The con-
tribution of these cytoskeletal components to the cell mechanotype
depends on their expression levels, structure and organization, which
can be modulated by filament crosslinkers (fascin, fimbrin, α-actinin,
spectrin, filamin and dystrophin), motor proteins (myosins), as well as
other regulatory proteins (Rho GTPases, profilin and cofilin). The
nucleus is also emerging as a major factor in regulating cell
deformability.21
The physical properties of cells and extracellular components in
the tumor microenvironment may have functional consequences
for cancer progression. As summarized in Figure 2, the mechanical
properties of cancer cells and their surrounding environment could be
implicated in many steps of metastasis.3 However, there is still much
to learn about which factors regulate the mechanotypes of cancer cells
and cells in the surrounding environment including tumor-associated
immune cells. Until now, only a short list defines critical genes and
signaling pathways that regulate cell mechanotype.22–24 Even less is
known about extrinsic factors, such as physiological influences and
environmental cues, which can also trigger changes in the mechanical
properties of cells.25,26
Expanding our knowledge of the physical factors that impact cancer
progression will help us to achieve a more integrated understanding of
this disease, ultimately allowing us to develop novel, more efficient
therapeutic drugs and preventative strategies. Here we explore the
hypothesis that the SNS—a physiological factor present in the tumor
microenvironment—may influence cell mechanotype to impact tumor
cell behavior and cancer progression.
We will review how SNS signaling through β-adrenoceptors
regulates cancer cell structure and how cell mechanotype is
linked to a malignant phenotype. Physical changes that occur during
cancer progression in immune cells and the ECM will also be
discussed. Finally, we will describe how an understanding of neural
regulation of cancer mechanobiology provides new opportunities for
therapeutic intervention, and new strategies for cancer diagnosis and
prognosis.
NEURAL SIGNALING REGULATES TUMOR CELL STRUCTURE
AND METASTASIS
A growing number of preclinical studies support the notion that SNS
signaling regulates metastasis. Metastasis is responsible for 90% of
deaths from solid cancers;27 once cancer metastasizes, there are limited
treatment options. Studies using mouse models of cancer demonstrate
that β-adrenergic signaling accelerates the progression of multiple
types of cancer.5,6,17,28–31 For example, the experience of chronic stress
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Figure 1 Hallmarks of cancer. The original six hallmarks of cancer:
(1) sustaining proliferative signaling, (2) evading growth suppressors,
(3) activating invasion and metastasis, (4) enabling replicative immortality,
(5) inducing angiogenesis and (6) resisting cell death, were first proposed in
2000 by Douglas Hanahan and Robert Weinberg.99 In 2011, four additional
next-generation cancer hallmarks were added: (7) avoiding immune
destruction, (8) tumor-promoting inflammation, (9) genome instability and
mutation and (10) deregulating cellular energetics.1 As we better understand
cancer, additional characteristics are emerging. Here we focus on the
physical properties of the tumor and microenvironment as an emerging new
hallmark.3,100 We show how misregulation by neural signaling can impact
these cancer hallmarks to promote disease progression. Permission to reuse
symbols for The Hallmarks of Cancer was granted by Elsevier.
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or pharmacological activation of SNS pathways with β-adrenergic
agonists, both increase tumor growth and metastatic dissemination.
In many studies, metastasis is the key step in cancer progression,
which is regulated by β-adrenergic signaling.5,6,17,28 Importantly,
mechanistic studies also demonstrate that inhibiting β-adrenergic
signaling with β-blockers prevents the adverse effect of SNS signaling
on cancer progression.5,6,17,28,29 In accordance with those preclinical
data, epidemiological studies support the idea that pharmacological
inhibition of β-adrenergic signaling improves cancer outcomes. Retro-
spective analyses of several cohorts show that cancer patients who are
incidentally exposed to β-blockers for treatment of hypertension are
likely to have reduced metastasis and improved survival (for summary
of these studies, see ref. 32). Although these clinical findings are
compelling, the results of these retrospective studies are limited to
association and cannot demonstrate causality or define mechanism.
Prospective randomized clinical studies will be essential to investigate
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Figure 2 Mechanical properties of cancer cells and the tumor microenvironment. The mechanical properties of cancer cells and the tumor microenvironment
may be implicated in various steps of tumor metastasis. There is an interplay between tumor cells in the primary tumor and their environment, as tumor cells
communicate with both the extracellular matrix (ECM) and immune cells. Metastatic tumor cells become dissociated from primary tumor and move into blood
vessels by passing through the basement membrane and ECM structures. Tumor cells in circulation are subject to various types of physical stresses such as
shear forces and friction. Contributing factors (blue) that can increase or decrease metastatic or invasive potential of tumor cells. Physical phenomena (red)
can be observed or measured during metastasis. The placement of sympathetic nerve fibers indicates cellular interactions that are regulated by neural
signaling. Images were adopted from Servier Medical Art by Servier (http://www.servier.com/Powerpoint-image-bank) and modified by the authors under the
following terms: CREATIVE COMMONS Attribution 3.0 Unported (CC BY 3.0).
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causal relationships between stress signaling and cancer outcomes in
patients.
At the cellular level, SNS signaling may regulate cancer progression
by inducing physical changes in cancer cells. For example, preclinical
studies show that SNS signaling increases invadopodia formation.19
These structural changes induce protrusions from the plasma mem-
brane that enable tumor cells to localize cell-derived proteases and
increase their capacity to invade.19 The formation of invadopodia is
accompanied by changes in focal adhesions that reduce cell migration
on two-dimensional surfaces. β-adrenergic regulation of focal
adhesion kinase—a key protein in the formation of focal adhesions
and invadopodia—also protects tumor cells from anoikis, which
increases their survival in circulation and promotes metastasis.33
Although the effects of the SNS on cancer cell mechanotype remain
to be investigated, activation of β-adrenoceptor signaling is known to
regulate the mechanical properties of other cell types, including blood
and muscle cells. Treating red blood cells and airway smooth muscle
cells with the β-adrenoceptor agonist, isoproterenol, makes these cells
more deformable.34,35 In contrast, treating primary cardiomyocytes
with the same drug makes these cells stiffer.36 These differences may
reflect signaling from different β-adrenoceptor subtypes and/or the
variations in readout from different measurement techniques that
depend on time and length scales (Box 1). Taken together, these
studies suggest that activation of β-adrenergic signaling plays a role in
regulating the deformability of various cell types. Future studies to
investigate the effects of β-adrenoceptor activation on the mechanical
properties of cancer cells could provide insight into the mechanism of
neural signaling in cancer progression.
CELL MECHANOTYPE IN MALIGNANT TRANSFORMATION
Although the effect of SNS activation on tumor cell deformability is
unknown, cell mechanotype appears to relate to invasive status.37–39
Recent experiments show that the invasive potential of cells correlates
with their deformability: softer or more deformable cells are more
invasive.38,39 The increased invasive potential of softer cells may be
explained by the idea that more deformable cells can move more easily
through tight gaps, which could assist their escape from a primary
tumor and invasion into surrounding ECM. There is also growing
evidence from in vitro experiments that malignant cancer cells are
softer or more deformable than benign cells. This is shown through
experiments on human cell lines derived from various tissues using
different mechanotyping methods, such as atomic force microscopy,40
optical stretching,41 deformability cytometry42 and parallel
microfiltration37 (Box 1, Figure 3). Cell deformability is associated
with the aggressiveness of tumor cells. For example, overexpression of
key transcription factors (Snail, Slug and Zeb1) that are involved in
epithelial-to-mesenchymal transition makes ovarian cancer cells
softer.37 Human mammary carcinoma (MCF-7) cells are more
deformable than their non-malignant mammary epithelial counter-
parts (MCF-10), and metastatic MCF-7 (modMCF-7) cells are even
more deformable than the less invasive MCF-7 cells.38 Human lung
adenocarcinoma cells with greater metastatic potential are also more
deformable than their less metastatic counterparts.39 Human bladder
epithelial cancer cells are more deformable than normal cells.43
Similarly, transformed fibroblasts are significantly more deformable
than normal untransformed fibroblasts.38,44 Taken together, malignant
cells across various types of cancers are more deformable than normal
cells. Moreover, more invasive tumor cells are softer or more
compliant than less invasive tumor cells. However, it is still unclear
whether increased cell deformability drives invasive potential and
metastasis, or whether it is simply a byproduct of selective pressures
that are applied during metastatic progression. Nevertheless, cell
mechanotype provides information about the invasive capacity of
cancer cells and is thus emerging as a complementary biomarker for
malignancy; such information may be potentially important for cancer
treatment and outcomes.
Deciphering the molecular origins of the altered mechanotype of
malignant cells is a complex challenge. Mechanotype is an emergent
property that can change as a result of multiple proteins, signaling
pathways and other factors. Changes in the structure and organization
of cytoskeletal networks are well known to alter cell mechanotype or
deformability; such structural changes are also linked to malignant
phenotype. For example, actin and microtubule content is increased in
high grade colon cancer and ovarian cancer cells compared to low
grade cancer cells.45,46 Differences in cytoskeletal architecture also
underlie variations in the deformability of melanoma cells; these
structural alterations are associated with in vivo metastatic potential in
mouse models.47 However, although changes in cytoskeletal architec-
ture are often observed, they do not always correlate with the softer
mechanotype of cancer cells: whereas mesenchymal-type ovarian
cancer cells are consistently softer than their epithelial-type counter-
parts, there is no consistent pattern of actin distribution or micro-
tubule organization that can explain the softer mechanotype.37 Cell
mechanotype can thus provide unique information as a biomarker to
classify the malignant status of a cell.
Cancer cell deformability also changes after treatment with
chemotherapeutic agents. Considering that many chemotherapy drugs
are designed to target cytoskeleton components and arrest cell
division, it is not surprising that anti-tumor drugs can alter cancer
cell mechanotype. For instance, taxanes and vinca alkaloids disrupt the
structure and dynamic of microtubules, and result in inhibition of
mitosis. The common chemotherapy compound, paclitaxel or Taxol,
is widely used in ovarian, breast and non-small cell lung cancers. By
binding to microtubules, this drug inhibits cell division, and also
makes cells stiffer or less deformable at concentrations of 0.1 to
1 000 nM.37 Whereas other studies show that endometrial and cervical
cancer cell lines treated with a much higher concentration (50 μM) of
Taxol become softer, or more deformable.48 These results suggest that
alteration in mechanotype with Taxol treatment is concentration
dependent. Moreover, different cell types (SKOV3 and OVCA433 vs
Ishikawa and HeLa) can exhibit different responses to the same drug.
Different measurement techniques (parallel microfiltration vs atomic
Box 1 Measuring mechanotype
The mechanical properties of biological materials can be characterized using
various techniques. Common methods to measure the mechanical properties of
cells and protein networks are summarized in Figure 3 (for details, see review3).
Many of these methods measure the displacement or change in shape of a cell or
protein network in response to well-defined physical stresses. Atomic force
microscopy is used to measure the viscoelastic properties of a single cell or
protein network with displacements down to 1 nm. Other techniques, such as
magnetic twisting cytometry and micropipette aspiration, can probe mechanical
properties over length scales of 1–10 μm. The deformability of whole cells can
also be measured by forcing cells to pass through smaller pores than cell size.
For example, the parallel microfiltration method, which applies air pressure to a
cell suspension to pass cells through a porous membrane, can measure the
relative deformability of different cell samples.37 Microfluidic deformability
cytometry measures whole-cell deformability by applying stretching extensional
flow to single cells.42 Active forces generated by the cell can be probed by
traction force microscopy, where displacements of the substrate that result from
contractile forces of the cell are measured.
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force microscopy) can also yield varying results depending on the
length scale of deformation (Box 1). Nevertheless, anti-tumor reagents
that target cytoskeletal components consistently alter the stiffness of
cancer cells. Interestingly, chemotherapeutic reagents that do not
target subcellular structures can also change the deformability of
cancer cells. For example, the DNA intercalating agent daunorubicin
(an anthracycline) and the corticosteroid dexamethasone both stiffen
acute lymphoblastic leukemia and acute myeloid leukemia cells.49
Treatment of metastatic tumor cells from patient effusions and
A549 human lung adenocarcinoma cells with green tea extract, which
exhibits anti-cancer properties, causes these cells to be stiffer.50
Although the molecular mechanisms of these clear differences in the
cancer cell mechanotype with transformation and with chemotherapy
exposure are still not completely understood, the physical property of
cells is emerging as a useful label-free biomarker. Currently, cancer
diagnosis and prognosis rely on various methods including screening
strategies, such as positron emission tomography, magnetic resonance
imaging and mammogram, immunohistochemical staining for various
biomarkers and analysis of genome sequences. These traditional
approaches may be complemented by analysis of tumor mechanotype.
For example, magnetic resonance elastography probes the elastic
properties of breast tissues in vivo.51 For analysis of excised tumor
cells, rapid, simple and scalable methods such as parallel micro-
filtration or microfluidic deformability cytometry could be used for
diagnosis, prognosis and detecting effects of drug treatments in
cancer patients.37,42 High throughput analysis of cell mechanotype
distinguishes circulating cancerous cells from normal cells in patients,
and demonstrates how this approach can enhance the accuracy
of pathological diagnosis, especially in borderline cases that are
challenging to assess by visual inspection alone.52
SNS REGULATES TUMOR-ASSOCIATED INFLAMMATION:
THE POTENTIAL ROLE OF MECHANOTYPE
The tumor microenvironment is highly complex and dynamic.
During tumor development, the local microenvironment evolves with
crosstalk among various residing cells including tumor, endothelial,
immune cells and fibroblasts. For example, tumor cells secrete
chemotactic factors that recruit immune cells into the tumor
microenvironment.53 The fate of carcinoma cells that leave the
primary tumor is determined by the balance between tumor-
promoting and tumor-suppressing immune cells, which regulate
whether tumor cells will be eliminated by the immune system or
escape immune surveillance. In the tumor microenvironment, hetero-
geneous populations of immune cells may be present that include both
tumor-promoting immune cells (including M2 macrophages, myeloid
derived suppressor cells and regulatory T cells) and tumor-suppressive
immune cells (including natural killer cells and CD8+ T cells).54
However, accumulating evidence shows that tumor-promoting
immune cells are selectively recruited to the established tumor
parenchyma and promote tumor progression.54 Macrophages play a
role in tumor progression as they are critical in inflammation,
modulating tumor microenvironment and promoting metastasis.55
In a highly pathogenic feedback loop, tumor cells respond to growth
factors produced by immune cells—particularly M2-skewed macro-
phages—that drive tumor cell proliferation.56 These interactions
between tumor cells and subverted macrophages also drive invasion of
tumor cells, leading to increased metastasis.57 Hence, identifying
factors that modulate the infiltration of immune cells into the tumor
microenvironment is essential to eradicating cancer.
Recruitment of macrophages to tumors is regulated by SNS
signaling, which accelerates metastasis6. Myeloid cells in bone marrow
express β-adrenergic receptors allowing them to recognize SNS-
derived signals in the form of stress neurotransmitters.58 β-adrenergic
signaling thus induces recruitment of macrophages into the
tumor parenchyma.6 Those tumor-associated macrophages facilitate
pro-metastatic events, such as increased angiogenesis, remodeling of
ECM, generation of pro-inflammatory environment, recruitment of
immune and cancer cells, and inhibition of anti-tumor immune
responses.6,17,59 Sensory neurons also play a well documented role in
inflammation (see review60 for details), however, this review is focused
on the role of SNS in tumor-associated inflammation.
Macrophages are not the only type of immune cell that are
regulated by SNS signaling and contribute to cancer progression.
Other tumor-associated immune cells, such as natural killer cells and
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Figure 3 Methodology for measuring the mechanical properties of cells. Different methods are used for measuring mechanical properties of cells (See Box 1).
Images are adapted from Servier Medical Art by Servier (http://www.servier.com/Powerpoint-image-bank) and modified by the authors under the following
terms: CREATIVE COMMONS Attribution 3.0 Unported (CC BY 3.0).
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T cells express β-adrenoceptors, and their function is sensitive to SNS
signaling.61,62 Studies in rat models of cancer show that neural
signaling suppresses natural killer cell activity and compromises host
resistance to natural killer-sensitive tumors.31 β-adrenergic activation
by endogenous neurotransmitters directly inhibits the generation of
anti-tumor cytotoxic T cells,63,64 and blocks the recruitment of
protective T cells into squamous cell carcinoma.65 This may be due,
in part, to the limiting effects of β-adrenergic signaling on the egress of
T lymphocytes from lymphoid organs.65 In addition, immune cells
themselves synthesize and secrete catecholamines to communicate
with other immune cells.66 Taken together, these data suggest that
β-adrenergic activation either by SNS signaling or immune cells plays a
critical role in directing the immune response in ways that favor
escape from immune surveillance and promote tumor progression.
The changes in immune cell migration and recruitment to tumors
that are activated by neural signaling are associated with cytoskeletal
changes in immune cells. For example, factors that regulate immune
cell chemotaxis to promote migration also induce structural changes
in immune cells. The formation of filopodia-like projections allows
immune cells to migrate in response to chemotactic molecular
gradients and interact with pathogens.67,68 Such changes in migration
behavior are also associated with altered cytoskeletal structure,67,69–71
which can also impact the mechanical properties of neutrophils,
monocytes, dendritic cells and lymphocytes. For example, micro-
pipette aspiration experiments show that cytoskeletal actin regulates
macrophage deformability: macrophages treated with cytochalasin B
are softer compared to vehicle-treated cells.72 In contrast, treatment
with colchicine, a microtubule-disrupting agent, has no observable
effect on cell deformability.72 These observations suggest that actin is a
predominant regulator of macrophage deformability. Disrupting the
connectivity between integrin and actin results in induction of a
transcriptional program characteristic of migratory dendritic cells,70
suggesting that changes in gene expression underlie changes in
immune cell migration. Given that the physical properties of immune
cells are important for their function,73 a more complete under-
standing of the impact of neural signaling on immune cell mechan-
otype will be important to understand the impact of this physiological
regulator on cancer progression.
PHYSICAL PROPERTIES OF THE ECM IN CANCER
PROGRESSION
The ECM is essential to every organ; this three-dimensional, non-
cellular structure is generated during early developmental stages and
plays a critical role in normal tissue development and function.74 In
mammals, the ECM is composed of about 300 proteins including
collagen, proteoglycans and glycoproteins, and provides physical
support for tissue integrity and elasticity. ECM composition and
structure are constantly remodeled by neighboring cells. For example,
the ECM is composed of both soluble and insoluble factors that are
secreted by stromal cells. To maintain homeostasis, tight regulation
of ECM degradation and generation is required.75 However,
an increasing number of studies suggest that dysregulated ECM
remodeling, such as aberrant deposition and loss of ECM components,
contributes to cancer progression.55
ECM stiffness plays a pivotal role in cancer progression.75,76 In fact,
palpation has been used for centuries to detect tumors, which are
generally stiffer than normal tissue. The rigidity of tumors originates
from the stiffer ECM due to desmoplasia.77 Changes in the rigidity of
ECM can activate integrins and growth factor receptors, which then
further alter matrix stiffness.40 This positive feedback loop can impact
malignant transformation similar to oncogenic signaling pathways.77
For example, interstitial fibrosis promotes breast tumorigenesis by
altering mammary ECM mechanics,78 and ECM stiffening is also
implicated in human breast cancer invasion and aggression.55 The
increased density of tumor ECM may also be a physical barrier to
effective treatment by chemotherapy.79
The stiffness of surrounding ECM also provides mechanical cues to
cancer cells. For example, cells alter their morphology and intracellular
tension in response to the stiffness of their substrate. When normal
mammary epithelial cells are cultivated in soft substrate, they form
acinar structures, whereas these cells grow in a monolayer when they
are cultured on a stiff surface.80 The mechanical properties of the cell
nucleus, another major determinant of cell mechanical properties, are
also directly influenced by matrix stiffness.81
Changes in the physical properties of the ECM may also influence
the behavior of immune cells. Aberrant ECM stiffness and changes to
ECM components in cancers may restrict or enhance immune cell
migration.75 Lysyl oxidase secreted by hypoxic breast tumor cells
mediates collagen crosslinking; and accumulated collagen deposition is
found in cancers that have increased ECM stiffness.75 Increased
density of ECM facilitates infiltration of tumor-promoting immune
cells (CD11b+ myeloid cells) as they adhere to cross-linked collagen.82
The density and orientation of the ECM fibers can also regulate
lymphocyte trafficking. T cells can migrate faster in ECM with loose
fibronectin and collagen, whereas they migrate more slowly in dense
ECM.83 Integrins that mediate cell–cell and cell–ECM adhesion are
also expressed in immune cells and influence cell migration and
retention. For example, CD8-T cells express integrin that bind to
collagen and aid their retention in the tumor microenvironment.84
Furthermore, proteases secreted by cancer cells result in proteolysis
and subsequent release of ECM fragments, which are known as
matrikines; these regulate immune and pro-inflammatory cell
behavior including immune cell migration. Such fragments of ECM
and collagen that are generated by matrix metalloproteinases attract
neutrophils to the sites of inflammation and promote dendritic cell
egress.85 ECM molecules and their derivatives may also affect the
function of immune cells to regulate tumor inflammation. Versican, a
large ECM proteoglycan, is upregulated in many cancers and activates
macrophages to produce interleukin-6 and tumor necrosis factor,
thereby establishing a pro-inflammatory microenvironment.86 Taken
together, these observations illustrate that ECM physical properties can
regulate immune cell migration and direct immune responses, and
thereby also affect cancer progression by determining how effectively
the immune cells can infiltrate into the tumor.
Although cancer progression can be modulated by both the physical
properties of the ECM and the SNS, it is still unclear how signaling
from SNS may affect the ECM.87 But as SNS regulates growth factors
and cytokines that can affect ECM remodeling, stress-responsive
neural signaling may impact the physical properties of the ECM to
affect cancer progression. For example, transforming growth factor-β
(TGFβ) is implicated in the production and crosslinking of collagen
in rat muscle cells.88 The expression of TGFβ is regulated by
norepinephrine, where it is implicated in interstitial fibrosis associated
with increased expression of ECM components such as fibronectin
and TGFβ in rat hearts.89 These observations suggest that β-adrenergic
signaling may regulate the density of components of the ECM.
CLINICAL IMPACT AND POTENTIAL TARGETS FOR
THERAPEUTIC BENEFIT
Our current body of knowledge on neural regulation of cancer and
mechanobiology provides several potential therapeutic interventions.
Links between neural signaling and cell mechanotype suggest that
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modulating SNS signaling could be used to change the physical
properties of tumor cells and tumor-associated immune cells to slow
cancer progression and improve survival. This may be particularly
useful in cancer subtypes with limited treatment options, such as triple
negative breast cancer, in which β-blocker use is linked to improved
outcome.90,91 The role of cell mechanotype and cell–ECM interactions
in modulating cancer progression suggests that monitoring the
mechanotype of tumor cells or tumor-associated immune cells could
complement other readouts of treatment efficacy. Until now, evidence
that β-blockers improve survival in cancer patients comes from
retrospective cohort datasets. Moreover, in vitro studies show that
inhibition of β-adrenergic signaling reduces the invasive potential of
cancer cells. It will be important to evaluate the effect of β-blockers on
cancer cell mechanotype and the physical properties of cancer cells
in patients, as well as on other cells including immune cells.
Understanding how β-adrenoceptor subtypes modulate the physical
properties of cells in the tumor microenvironment will also provide
deeper insight into cancer progression. For example, our recent studies
show a critical role for β2-adrenoceptor signaling in SNS regulation of
cell structure and invasion;19,92 The β3-adrenoceptor has also been
implicated in cancer progression.30,93
Pharmacological interventions that modulate cell or ECM mechan-
ical properties could also be used to slow cancer progression. For
example, ECM-modulating enzyme inhibitors (for example, inhibitors
of matrix metalloproteases) effectively slow cancer progression in
preclinical models of cancer, although their efficacy has been
disappointing in the cancer clinic.94 However, recent Phase 2 clinical
trials have evaluated the effects of simtuzumab, an antibody that
inhibits lysyl oxidase-like 2, in colorectal adenocarcinoma and
pancreatic adenocarcinoma (NCT01479465 and NCT01472198). The
TGFβ-inhibitory antibody is also being evaluated in multiple cancers
including breast, lung and glioma; TGFβ is critical for regulating the
expression of proteins that comprise the ECM (NCT01401062,
NCT02581787 and NCT01472731).
New technologies that probe cell mechanotype may be used to
identify patients who may benefit from interventions that target the
physical properties of cancer cells. For example, deformability
cytometry can define whether cells from pleural effusions are
malignant or benign.95 The observation that malignant cells are more
deformable than normal cells38,52 suggests that mechanical bio-
markers may enhance diagnosis, either in a label-free manner or in
combination with current immunohistological methods of diagnosis.
In addition, the mechanical properties of cells can be used as an
indicator of drug response. As discussed earlier, many cancer drugs
target the cytoskeleton and alter the viscoelastic properties of
cells.37,48,96 Moreover, cell mechanotype can identify cells that are
resistant to common chemotherapy drugs. Cisplatin-resistant ovarian
cancer cells are less deformable due to modification of their actin
cytoskeleton.97 The altered mechanotype of chemoresistant cells can
be utilized in large-scale drug screening using cell deformability
as a readout; mechanotype measurements are advantageous for
high-throughput screening as an inexpensive, label-free approach.
Indeed, we have identified compounds that reduce cell deformability
from a small molecule mechanotype screen; these compounds also
inhibit invasion and anchorage independent growth of tumor cells
(unpublished data). Such a screening method may be adapted for use
with clinical cancer samples to define the drug sensitivity of cancer
cells from patients. This may help to guide choice of therapeutic
strategies, which could address the challenge of chemoresistance in
cancer treatment.
Cell mechanotype may also be used as a prognostic tool to identify
patients with advanced disease. As metastasis accounts for most cancer
deaths, secondary tumors are an important prognostic factor in cancer
patients. As metastasizing cancer cells travel via the circulatory system,
detection of circulating tumor cells (CTCs) in vasculature, is one way
to predict the degree of metastasis. CTCs can be isolated based on
their biophysical properties, as CTCs have greater nuclear to cyto-
plasmic ratio and are a larger size than normal cells.98 Cell mechan-
otype may thus be an effective prognostic biomarker for CTCs.98 In a
similar way, detection of CTCs may be applied to determine the
presence of residual cancer cells or relapse of tumor after treatment.
Significant advances in our understanding of cancer biology are
emerging with expanded knowledge of cancer immunology and the
development of techniques to evaluate the physical properties of
tumor cells and their microenvironment. However, a deeper under-
standing of how physiological factors such as SNS signaling modulate
mechanical properties of tumor cells, immune cells and the ECM will
provide novel targets for new therapies that may help to treat
metastasis and improve cancer survival. Cancer is a complex disease.
Achieving a more integrated understanding of the relationships
between physiological regulators and the physical properties of tumor
cells and their environment will enable a more holistic perspective on
cancer, and ultimately more effective treatments.
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